13F filings
Paradigm BioCapital
$4.9B to $5.3B. Includes price moves and buying or selling; not the fund's return.
Free on iOS and Android.
Sector mix of the disclosed holdings
by disclosed valueLargest holdings
all 28 positions| Holding | Value | Shares | % of 13F value |
|---|---|---|---|
| RVMDRevolution Medicines | $1.2B | 6,361,323 | 22.3% |
| NUVLNuvalent | $731.7M | 5,924,433 | 13.7% |
| EWTXEdgewise Therapeutics | $415.1M | 10,215,455 | 7.8% |
| GMABGenmab A/S | $360.8M | 13,133,131 | 6.8% |
| SYRESpyre Therapeutics | $341.0M | 3,840,778 | 6.4% |
| APGEApogee Therapeutics | $209.2M | 1,576,385 | 3.9% |
| ORKAOruka Therapeutics | $204.1M | 2,144,526 | 3.8% |
| TNGXTango Therapeutics | $198.7M | 6,357,523 | 3.7% |
| BLTEBelite Bio | $189.8M | 1,232,877 | 3.6% |
| ERASErasca | $175.0M | 9,550,000 | 3.3% |
| TARSTarsus Pharmaceuticals | $174.7M | 2,775,649 | 3.3% |
| ALNYAlnylam Pharmaceuticals | $144.5M | 480,000 | 2.7% |
| INSMInsmed | $141.4M | 1,325,977 | 2.6% |
| MBXMBX Biosciences | $138.4M | 2,508,015 | 2.6% |
| PCVXVaxcyte | $123.7M | 2,127,852 | 2.3% |
| VRDNViridian Therapeutics | $123.5M | 6,723,788 | 2.3% |
| OLMAOlema Pharmaceuticals | $108.5M | 8,670,576 | 2.0% |
| JBIOJade Biosciences | $63.5M | 2,857,405 | 1.2% |
| TYRATyra Biosciences | $58.4M | 1,828,607 | 1.1% |
| ASMBAssembly Biosciences | $42.7M | 1,553,748 | 0.8% |
| EYPTEyePoint Pharmaceuticals | $41.3M | 2,890,397 | 0.8% |
| ACHVAchieve Life Sciences | $32.3M | 4,951,856 | 0.6% |
| VORVor Biopharma | $32.2M | 1,750,000 | 0.6% |
| MPLTMapLight Therapeutics | $24.6M | 685,852 | 0.5% |
| KARDKardigan | $21.5M | 900,000 | 0.4% |
| LXEOLexeo Therapeutics | $19.4M | 4,175,382 | 0.4% |
| EDITEditas Medicine | $18.1M | 5,586,625 | 0.3% |
| IVAInventiva | $15.1M | 4,000,000 | 0.3% |
% of 13F value is the position's value against the whole disclosed 13F value, so the rows shown here do not sum to 100% unless every position is listed.
GetSignal pushes each new 13F to your phone as it is filed, with the positions that changed and the companies behind them. Free on iOS and Android.
What Paradigm BioCapital bought and sold in Q2 2026
15 largest moves| Holding | Move | Share change | Est. amount moved | Value after |
|---|---|---|---|---|
| ACLXArcellx | Exited | -100% | -$663.0M | $0 |
| SYRESpyre Therapeutics | Added | +96.2% | +$167.2M | $341.0M |
| PCVXVaxcyte | Trimmed | -55.6% | -$154.9M | $123.7M |
| ALNYAlnylam Pharmaceuticals | New | new | +$144.5M | $144.5M |
| CNTACentessa Pharmaceuticals | Exited | -100% | -$142.0M | $0 |
| GMABGenmab A/S | Added | +64.8% | +$141.9M | $360.8M |
| MBXMBX Biosciences | New | new | +$138.4M | $138.4M |
| TERNTerns Pharmaceuticals | Exited | -100% | -$116.9M | $0 |
| EWTXEdgewise Therapeutics | Added | +38.7% | +$115.8M | $415.1M |
| CYTKCytokinetics | Exited | -100% | -$97.6M | $0 |
| ABVXAbivax | Exited | -100% | -$86.0M | $0 |
| MAZEMaze Therapeutics | Exited | -100% | -$81.9M | $0 |
| NUVLNuvalent | Added | +11.3% | +$74.1M | $731.7M |
| TNGXTango Therapeutics | Added | +58.6% | +$73.4M | $198.7M |
| VRDNViridian Therapeutics | Added | +113.5% | +$65.7M | $123.5M |
A change is this filing measured against the one before it. Est. amount moved is the shares added or sold, priced at the Jun 30, 2026 close. An estimate: a 13F gives no trade prices or dates. For a sold-out position, its value at the previous quarter end.
Questions
What does Paradigm BioCapital hold?
Paradigm BioCapital disclosed 28 positions worth $5.3B in the Q2 2026 13F filing. The largest is RVMD at 22.3% of the disclosed value. A 13F lists US-listed stock and options on it; short sales and cash are not in it.
What did Paradigm BioCapital buy and sell last quarter?
Comparing the Q2 2026 filing with the quarter before, the largest moves were selling out of ACLX, adding to SYRE, trimming PCVX and opening a position in ALNY. Changes are measured against the previous filing, not against trades, because a 13F does not disclose trades.
How current is this?
This is the Q2 2026 filing, covering positions held on Jun 30, 2026 and filed with the SEC on Aug 14, 2026. A 13F is due 45 days after the quarter ends, so the most recent filing is always at least six weeks behind the market, and the manager may have changed the book since.
How to read a 13F
WHAT THE FILING COVERS
Positions are as disclosed to the SEC on Form 13F and are not investment advice. How this data is sourced, and what it cannot tell you, is on the methodology page. How the filing itself works is explained in our guide to Form 13F.
Checked for newer filings on Oct 26, 2026.